Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein

Virology

Volumn 512, Issue , 2017, Pages 161-171

  Galan Navarro, Clara ^a,b   Rincon Restrepo, Marcela ^b   Zimmer, Gert ^c   Ollmann Saphire, Erica ^d   Hubbell, Jeffrey A ^b,e   Hirosue, Sachiko ^b   Swartz, Melody A ^b,e   Kunz, Stefan ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EPFL   (Switzerland)

^c INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Anti viral antibodies; Lassa virus; Nanocarrier; Polymersomes; Subunit vaccine

Indexed keywords

ANTIGEN; EPITOPE; GLYCOPROTEIN; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOCARRIER; POLYMERSOME; UNCLASSIFIED DRUG; NANOMATERIAL; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; LASSA VIRUS; LIMIT OF QUANTITATION; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRION; A-549 CELL LINE; ANIMAL; C57BL MOUSE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; LASSA FEVER; METABOLISM; PHYSIOLOGY;

A549 CELLS; ANIMALS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GLYCOPROTEINS; HEK293 CELLS; HUMANS; IMMUNITY, HUMORAL; LASSA FEVER; LASSA VIRUS; MICE; MICE, INBRED C57BL; NANOSTRUCTURES; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 85030120375     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2017.09.013     Document Type: Article

References (61)

1. Andersen, K.G., Shapiro, B.J., Matranga, C.B., Sealfon, R., Lin, A.E., Moses, L.M., Folarin, O.A., Goba, A., Odia, I., Ehiane, P.E., Momoh, M., England, E.M., Winnicki, S., Branco, L.M., Gire, S.K., Phelan, E., Tariyal, R., Tewhey, R., Omoniwa, O., Fullah, M., Fonnie, R., Fonnie, M., Kanneh, L., Jalloh, S., Gbakie, M., Saffa, S., Karbo, K., Gladden, A.D., Qu, J., Stremlau, M., Nekoui, M., Finucane, H.K., Tabrizi, S., Vitti, J.J., Birren, B., Fitzgerald, M., McCowan, C., Ireland, A., Berlin, A.M., Bochicchio, J., Tazon-Vega, B., Lennon, N.J., Ryan, E.M., Bjornson, Z., Milner, D.A. Jr., Lukens, A.K., Broodie, N., Rowland, M., Heinrich, M., Akdag, M., Schieffelin, J.S., Levy, D., Akpan, H., Bausch, D.G., Rubins, K., McCormick, J.B., Lander, E.S., Gunther, S., Hensley, L., Okogbenin, S., Viral Hemorrhagic Fever, C., Schaffner, S.F., Okokhere, P.O., Khan, S.H., Grant, D.S., Akpede, G.O., Asogun, D.A., Gnirke, A., Levin, J.Z., Happi, C.T., Garry, R.F., Sabeti, P.C., Clinical sequencing uncovers origins and evolution of lassa virus. Cell 162 (2015), 738–750.
2. Baumjohann, D., Ansel, K.M., Tracking early T follicular helper cell differentiation in vivo. Methods Mol. Biol. 1291 (2015), 27–38.
3. Berger Rentsch, M., Zimmer, G., A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PloS One, 6, 2011, e25858.
4. Bergthaler, A., Flatz, L., Verschoor, A., Hegazy, A.N., Holdener, M., Fink, K., Eschli, B., Merkler, D., Sommerstein, R., Horvath, E., Fernandez, M., Fitsche, A., Senn, B.M., Verbeek, J.S., Odermatt, B., Siegrist, C.A., Pinschewer, D.D., Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol., 7, 2009, e1000080.
5. Borio, L., Inglesby, T., Peters, C.J., Schmaljohn, A.L., Hughes, J.M., Jahrling, P.B., Ksiazek, T., Johnson, K.M., Meyerhoff, A., O'Toole, T., Ascher, M.S., Bartlett, J., Breman, J.G., Eitzen, E.M. Jr., Hamburg, M., Hauer, J., Henderson, D.A., Johnson, R.T., Kwik, G., Layton, M., Lillibridge, S., Nabel, G.J., Osterholm, M.T., Perl, T.M., Russell, P., Tonat, K., Hemorrhagic fever viruses as biological weapons: medical and public health management. Jama 287 (2002), 2391–2405.
6. Borrow, P., Oldstone, M.B., Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus. J. Virol. 66 (1992), 7270–7281.
7. Bowden, T.A., Crispin, M., Graham, S.C., Harvey, D.J., Grimes, J.M., Jones, E.Y., Stuart, D.I., Unusual molecular architecture of the machupo virus attachment glycoprotein. J. Virol. 83 (2009), 8259–8265.
8. Branco, L.M., Grove, J.N., Geske, F.J., Boisen, M.L., Muncy, I.J., Magliato, S.A., Henderson, L.A., Schoepp, R.J., Cashman, K.A., Hensley, L.E., Garry, R.F., Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol. J., 7, 2010, 279.
9. Burton, D.R., Mascola, J.R., Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16 (2015), 571–576.
10. Burton, D.R., Poignard, P., Stanfield, R.L., Wilson, I.A., Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337 (2012), 183–186.
11. Burton, D.R., Saphire, E.O., Parren, P.W., A model for neutralization of viruses based on antibody coating of the virion surface. Curr. Top. Microbiol Immunol. 260 (2001), 109–143.
12. Casella, C.R., Mitchell, T.C., Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol. Life Sci. 65 (2008), 3231–3240.
13. Cohen-Dvashi, H., Cohen, N., Israeli, H., Diskin, R., Molecular Mechanism for LAMP1 Recognition by Lassa Virus. J. Virol. 89 (2015), 7584–7592.
14. Cross, R.W., Mire, C.E., Branco, L.M., Geisbert, J.B., Rowland, M.M., Heinrich, M.L., Goba, A., Momoh, M., Grant, D.S., Fullah, M., Khan, S.H., Robinson, J.E., Geisbert, T.W., Garry, R.F., Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antivir. Res 133 (2016), 218–222.
15. Datta, S., Budhauliya, R., Das, B., Chatterjee, S., Vanlalhmuaka, Veer, V., Next-generation sequencing in clinical virology: discovery of new viruses. World J. Virol. 4 (2015), 265–276.
16. Dutko, F.J., Oldstone, M.B., Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J. General. Virol. 64:Pt 8 (1983), 1689–1698.
17. Fazekas de St Groth, B., Smith, A.L., Higgins, C.A., T cell activation: in vivo veritas. Immunol. Cell Biol. 82 (2004), 260–268.
18. Fisher-Hoch, S.P., Tomori, O., Nasidi, A., Perez-Oronoz, G.I., Fakile, Y., Hutwagner, L., McCormick, J.B., Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. Bmj 311 (1995), 857–859.
19. Geisbert, T.W., Jahrling, P.B., Exotic emerging viral diseases: progress and challenges. Nat. Med. 10 (2004), S110–S121.
20. Goncalves, A.R., Moraz, M.L., Pasquato, A., Helenius, A., Lozach, P.Y., Kunz, S., Role of DC-SIGN in Lassa Virus Entry into Human Dendritic Cells. J. Virol. 87 (2013), 11504–11515.
21. Hastie, K.M., Igonet, S., Sullivan, B.M., Legrand, P., Zandonatti, M.A., Robinson, J.E., Garry, R.F., Rey, F.A., Oldstone, M.B., Saphire, E.O., Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV. Nat. Struct. Mol. Biol. 23 (2016), 513–521.
22. Hastie, K.M., Zandonatti, M.A., Kleinfelter, L.M., Heinrich, M.L., Rowland, M.M., Chandran, K., Branco, L.M., Robinson, J.E., Garry, R.F., Saphire, E.O., Structural basis for antibody-mediated neutralization of Lassa virus. Science 356 (2017), 923–928.
23. Igonet, S., Vaney, M.C., Vonhrein, C., Bricogne, G., Stura, E.A., Hengartner, H., Eschli, B., Rey, F.A., X-ray structure of the arenavirus glycoprotein GP2 in its postfusion hairpin conformation. Proc. Natl. Acad. Sci. USA 108 (2011), 19967–19972.
24. Illick, M.M., Branco, L.M., Fair, J.N., Illick, K.A., Matschiner, A., Schoepp, R., Garry, R.F., Guttieri, M.C., Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding. Virol. J., 5, 2008, 161.
25. Johnson, K.M., McCormick, J.B., Webb, P.A., Smith, E.S., Elliott, L.H., King, I.J., Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 155 (1987), 456–464.
26. Karlsson Hedestam, G.B., Fouchier, R.A., Phogat, S., Burton, D.R., Sodroski, J., Wyatt, R.T., The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol 6 (2008), 143–155.
27. Kunz, S., Edelmann, K.H., de la Torre, J.C., Gorney, R., Oldstone, M.B., Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. Virology 314 (2003), 168–178.
28. Kunz, S., Rojek, J.M., Perez, M., Spiropoulou, C.F., Oldstone, M.B., Characterization of the interaction of lassa fever virus with its cellular receptor alpha-dystroglycan. J. Virol. 79 (2005), 5979–5987.
29. Kunz, S., Sevilla, N., McGavern, D.B., Campbell, K.P., Oldstone, M.B., Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J. Cell Biol. 155 (2001), 301–310.
30. Kunz, S., Sevilla, N., Rojek, J.M., Oldstone, M.B., Use of alternative receptors different than alpha-dystroglycan by selected isolates of lymphocytic choriomeningitis virus. Virology 325 (2004), 432–445.
31. Lee, A.M., Cruite, J., Welch, M.J., Sullivan, B., Oldstone, M.B., Pathogenesis of Lassa fever virus infection: i. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus. Virology, 2013.
32. Lefterova, M.I., Suarez, C.J., Banaei, N., Pinsky, B.A., Next-generation sequencing for infectious disease diagnosis and management: a report of the association for molecular pathology. J. Mol. Diagn. 17 (2015), 623–634.
33. Li, S., Sun, Z., Pryce, R., Parsy, M.L., Fehling, S.K., Schlie, K., Siebert, C.A., Garten, W., Bowden, T.A., Strecker, T., Huiskonen, J.T., Acidic pH-Induced conformations and LAMP1 binding of the lassa virus glycoprotein spike. PLoS Pathog., 12, 2016, e1005418.
34. McCormick, J.B., Fisher-Hoch, S.P., Lassa fever. Curr. Top. Microbiol Immunol. 262 (2002), 75–109.
35. McCormick, J.B., King, I.J., Webb, P.A., Johnson, K.M., O'Sullivan, R., Smith, E.S., Trippel, S., Tong, T.C., A case-control study of the clinical diagnosis and course of Lassa fever. J. Infect. Dis. 155 (1987), 445–455.
36. McCormick, J.B., King, I.J., Webb, P.A., Scribner, C.L., Craven, R.B., Johnson, K.M., Elliott, L.H., Belmont-Williams, R., Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314 (1986), 20–26.
37. McCormick, J.B., Mitchell, S.W., Kiley, M.P., Ruo, S., Fisher-Hoch, S.P., Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J. Med Virol. 37 (1992), 1–7.
38. Moeschler, S., Locher, S., Conzelmann, K.K., Kramer, B., Zimmer, G., Quantification of Lyssavirus-neutralizing antibodies using vesicular stomatitis virus pseudotype particles. Viruses, 8, 2016.
39. Moraz, M.L., Pythoud, C., Turk, R., Rothenberger, S., Pasquato, A., Campbell, K.P., Kunz, S., Cell entry of Lassa virus induces tyrosine phosphorylation of dystroglycan. Cell Microbiol 15 (2013), 689–700.
40. Olschlager, S., Flatz, L., Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. PLoS Pathog., 9, 2013, e1003212.
41. Oppliger, J., Torriani, G., Herrador, A., Kunz, S., Lassa virus cell entry via dystroglycan involves an unusual pathway of macropinocytosis. J. Virol., 2016.
42. Parren, P.W., Burton, D.R., The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77 (2001), 195–262.
43. Pasqual, G., Rojek, J.M., Masin, M., Chatton, J.Y., Kunz, S., Old world arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. PLoS Pathog., 7, 2011, e1002232.
44. Prescott, J.B., Marzi, A., Safronetz, D., Robertson, S.J., Feldmann, H., Best, S.M., Immunobiology of Ebola and Lassa virus infections. Nat. Rev. Immunol., 2017.
45. Radoshitzky, S.R., Abraham, J., Spiropoulou, C.F., Kuhn, J.H., Nguyen, D., Li, W., Nagel, J., Schmidt, P.J., Nunberg, J.H., Andrews, N.C., Farzan, M., Choe, H., Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 446 (2007), 92–96 (Epub 2007 Feb 2007).
46. Robinson, J.E., Hastie, K.M., Cross, R.W., Yenni, R.E., Elliott, D.H., Rouelle, J.A., Kannadka, C.B., Smira, A.A., Garry, C.E., Bradley, B.T., Yu, H., Shaffer, J.G., Boisen, M.L., Hartnett, J.N., Zandonatti, M.A., Rowland, M.M., Heinrich, M.L., Martinez-Sobrido, L., Cheng, B., de la Torre, J.C., Andersen, K.G., Goba, A., Momoh, M., Fullah, M., Gbakie, M., Kanneh, L., Koroma, V.J., Fonnie, R., Jalloh, S.C., Kargbo, B., Vandi, M.A., Gbetuwa, M., Ikponmwosa, O., Asogun, D.A., Okokhere, P.O., Follarin, O.A., Schieffelin, J.S., Pitts, K.R., Geisbert, J.B., Kulakoski, P.C., Wilson, R.B., Happi, C.T., Sabeti, P.C., Gevao, S.M., Khan, S.H., Grant, D.S., Geisbert, T.W., Saphire, E.O., Branco, L.M., Garry, R.F., Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun., 7, 2016, 11544.
47. Rojek, J.M., Moraz, M.L., Pythoud, C., Rothenberger, S., Van der Goot, F.G., Campbell, K.P., Kunz, S., Binding of Lassa virus perturbs extracellular matrix-induced signal transduction via dystroglycan. Cell Microbiol 14 (2012), 1122–1134.
48. Rojek, J.M., Sanchez, A.B., Nguyen, N.T., de la Torre, J.C., Kunz, S., Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J. Virol. 82 (2008), 7677–7687.
49. Sanchez, A., Pifat, D.Y., Kenyon, R.H., Peters, C.J., McCormick, J.B., Kiley, M.P., Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. J. Gen. Virol. 70 (1989), 1125–1132.
50. Scott, E.A., Stano, A., Gillard, M., Maio-Liu, A.C., Swartz, M.A., Hubbell, J.A., Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. Biomaterials 33 (2012), 6211–6219.
51. Sommerstein, R., Flatz, L., Remy, M.M., Malinge, P., Magistrelli, G., Fischer, N., Sahin, M., Bergthaler, A., Igonet, S., Ter Meulen, J., Rigo, D., Meda, P., Rabah, N., Coutard, B., Bowden, T.A., Lambert, P.H., Siegrist, C.A., Pinschewer, D.D., Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog., 11, 2015, e1005276.
52. Sommerstein, R., Ramos da Palma, J., Olschlager, S., Bergthaler, A., Barba, L., Lee, B.P., Pasquato, A., Flatz, L., Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness. J. Virol. 88 (2014), 8340–8348.
53. Stano, A., Scott, E.A., Dane, K.Y., Swartz, M.A., Hubbell, J.A., Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. Biomaterials 34 (2013), 4339–4346.
54. Stephenson, E.H., Larson, E.W., Dominik, J.W., Effect of environmental factors on aerosol-induced Lassa virus infection. J. Med Virol. 14 (1984), 295–303.
55. Sweileh, W.M., Global research trends of World Health Organization's top eight emerging pathogens. Glob. Health, 13, 2017, 9.
56. Tiller, T., Busse, C.E., Wardemann, H., Cloning and expression of murine Ig genes from single B cells. J. Immunol. Methods 350 (2009), 183–193.
57. Viskovska, M., Anish, R., Hu, L., Chow, D.C., Hurwitz, A.M., Brown, N.G., Palzkill, T., Estes, M.K., Prasad, B.V., Probing the sites of interactions of rotaviral proteins involved in replication. J. Virol. 88 (2014), 12866–12881.
58. Walker, L.M., Burton, D.R., Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22 (2010), 358–366.
59. Webster, D.M., Sundaram, P., Byrne, M.E., Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur. J. Pharm. Biopharm. 84 (2013), 1–20.
60. Yun, N.E., Walker, D.H., Pathogenesis of Lassa fever. Viruses 4 (2012), 2031–2048.
61. Zeitlin, L., Whaley, K.J., Olinger, G.G., Jacobs, M., Gopal, R., Qiu, X., Kobinger, G.P., Antibody therapeutics for Ebola virus disease. Curr. Opin. Virol. 17 (2016), 45–49.